a

is available at the end of the articleIntroduction Human epithelial ovarian cancer (EOC) is one of malig-nant tumors in gynecological cancers and currently remains to be the number one the first leading cause of cancer-related deaths in women due to factors such as failure for its early dectection and diagnosis, its proneness to pelvic and peritoneal metastasis, and its resistance to chemotherapy after recurrence. Although many studies have been published in the past decade and have contrib-uted to the advance of the knowledge in this field, the com-plex biology of EOC is still insufficiently understood [1,2]. Therefore, more recent studies have focused on the mo-lecular mechanisms underlying the EOC progression and the new strategies for early clinical diagnosis and effective therapy [3,4]. Recent studies have demonstrated that cancer stem cells (CSCs) are responsible for tumour-initiating potential, me-tastasis and eventual relapse. Thus, the treatments that target CSCs may lead to the discovery of effective method